• Haemophilus influenzae IgG Parallel Testing, ELISA
• Poliovirus Antibody, Neutralization
• Streptococcus pneumoniae IgG Antibody (12 Serotypes), MAID
• Streptococcus pneumoniae IgG Antibody (14 Serotypes), MAID
• Streptococcus pneumoniae IgG Antibody (6 Serotypes), MAID
• Streptococcus pneumoniae IgG Antibody (7 Serotypes), MAID

• Coccidioides immitis Identification, DNA Probe
• Coccidioides Antibody, Complement Fixation, Serum
• Coccidioides Antibody Panel, CF and ID (CSF)
• Coccidioides Antibody Panel, CF and LA
• Coccidioides Antibody Panel, CF, ID and LA
• Coccidioides Antibody, CF and ID, Serum
• Coccidioides Antibody, Complement Fixation, CSF
• Coccidioides Antibody, Immunodiffusion, CSF
• Coccidioides Antibody, Immunodiffusion, Serum
• Coccidioides Antibody, LA

• Bacterial Culture, Aerobic, Routine
• Bacterial Culture, Aerobic, Special
• Bacterial Culture, Anaerobic, Routine

The sensitivity of this test is highly dependent upon proper collection of an adequate patient specimen and upon the age of the lesion. Specimens should be collected by scraping the base of a fresh vesicular lesion. A sufficient number of cells from the lesion must be collected for optimal performance of this test. Poor sample quality may cause direct specimens to be falsely negative or inadequate for analysis.

This test is approved for New York patient testing.

Varicella-Zoster virus (VZV) is a member of the Herpesviridae family that causes chickenpox as a primary infection and can reactivate later in life as herpes zoster or shingles. VZV infection in immunocompromised individuals often leads to a progressive disease state involving multiple organs. The detection of Varicella-Zoster Virus (VZV) DNA is based upon the real-time amplification and detection of specific VZV genomic DNA sequences by PCR from total DNA extracted from the specimen.

This test is not approved for New York patient testing.

The use of centrifugation-enhanced shell vial culture methods combined with sensitive monoclonal antibody staining technique reduces the time for isolation of Varicella-Zoster Virus to four days. Isolation ordinarily take as much as 7 to 14 days using conventional tube culture methods.

This test is approved for New York patient testing.

Varicella-Zoster virus (VZV) causes chickenpox as a primary infection and can reactivate later in life as herpes zoster or shingles. In immunocompromised individuals VZV infection often leads to a progressive disease state involving multiple organs. If VZV DNA is detected in the qualitative assay, the specimen will reflex to the VZV Quantitative Real-Time PCR (Focus Unit Code 45200) for an additional charge. The quantitative range if reflexed is 500 - 35,000,000 VZV DNA copies/mL.

This test is not approved for New York patient testing.

Detection of intrathecally-produced organism-specific antibodies in CSF indicates central nervous system infection. However, serum levels of organism-specific antibodies, blood-brain barrier integrity, and possible CSF contamination by blood should be considered when assessing CSF results.

This test is approved for New York patient testing.

Detection of intrathecally-produced organism-specific antibodies in CSF indicates central nervous system infection. However, serum levels of organism-specific antibodies, blood-brain barrier integrity, and possible CSF contamination by blood should be considered when assessing CSF results.

This test is approved for New York patient testing.

Varicella-Zoster virus (VZV) is a member of the Herpesviridae family that causes chickenpox as a primary infection and can reactivate later in life as herpes zoster or shingles. VZV infection in immunocompromised individuals often leads to a progressive disease state involving multiple organs. The detection of Varicella-Zoster Virus (VZV) DNA is based upon the real-time amplification and detection of specific VZV genomic DNA sequences by PCR from total DNA extracted from the specimen. The quantitative range of this assay is 500 - 2,000,000 VZV DNA copies/mL.

This test is not approved for New York patient testing.

Detection of intrathecally-produced organism-specific antibodies in CSF indicates central nervous system infection. However, serum levels of organism-specific antibodies, blood-brain barrier integrity, and possible CSF contamination by blood should be considered when assessing CSF results.

This test is available for New York patient testing.

A positive titer (>=1:4) by anticomplement immunofluorescence (ACIF) indicates a history of past infection by Varicella-Zoster virus (VZV). This antibody is usually detectable within 2 days after the onset of rash and is, thereafter, detectable for life. Conversely, the absence of detectable antibody can be used as evidence of susceptibility to varicella (chickenpox).

This test is approved for New York patient testing.

Varicella-Zoster virus (VZV) causes chickenpox and when reactivated, potentially decades later, causes shingles. Twenty percent of adults will develop shingles, a rash or blister of the skin that may cause severe pain. VZV IgG, EIA reliably measures immunity due to previous infection, but is unsuitable for detection of post-vaccination immune status.

The detection of IgM antibody to Varicella-Zoster virus (VZV) usually indicates recent/current infection but occasionally may indicate reactivation of VZV or infection with other Herpesviruses. Definitive evidence for recent exposure to VZV would be detection of increasing anti-complement immunofluoresence (ACIF) titers between acute and convalescent sera, see Focus Unit Code 4400. IgM antibody typically remains detectable two to three months after initial infection.

This test is available for New York patient testing.

Detection of intrathecally-produced organism-specific antibodies in CSF indicates central nervous system infection. However, serum levels of organism-specific antibodies, blood-brain barrier integrity, and possible CSF contamination by blood should be considered when assessing CSF results.

This test is approved for New York patient testing.

A four-fold rise in titer between acute and convalescent sera is required for serodiagnosis of acute chickenpox, zoster, or other diseases caused by Varicella-Zoster virus (VZV). Single titers >=1:256 are considered suggestive of recent or active infection. Please note: This procedure is not intended for determinations of immunity or susceptibility to VZV. For this use, please request the anticomplement immunofluorescence (ACIF) procedure Focus Unit Code 41015, a test that has superior sensitivity.

This test is approved for New York patient testing.

VDRL is the test of choice for assessing CNS involvement in syphilis.

This test is approved for New York patient testing.

The VDRL is a nontreponemal test to detect antibody to the lipoidal antigen of T. pallidum. Nontreponemal tests for syphilis become reactive 4-6 weeks after infection with titers peaking during secondary to early latent stage. Treatment in the primary or secondary stages usually results in a rapid decline in titer. Treatment given in latent or late stages has less effect on antibody titers and the test may remain reactive at low titers indefinitely. Nontreponemal tests lack specificity and positive sera should be confirmed by Treponema pallidum antibody (FTA-ABS).

This test is approved for New York patient testing.

Culture for measles, mumps and rubella viruses, CMV, Adenovirus, VZV, and other viruses. A variety of cell lines are inoculated and held for up to 3 weeks to detect characteristic cytopathic effects followed by identification using biochemical and immunological methods. PLEASE INDICATE SUSPECTED VIRUS(ES) ON TEST REQUEST FORM.

This test is approved for New York patient testing.

• Varicella Zoster Virus (VZV) DNA, Qualitative Real-Time PCR

• Acyclovir, HPLC
• Ganciclovir, HPLC

• Antimicrobial Susceptibility Testing

• Bacterial Culture, Screen for Vancomycin-Resistant Enterococcus (Stool)